DPAGT1-视角作为一种抗癌药物标
Michio Kurosu1, Katsuhiko Mitachi1
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38163, USA.
Molecules (Basel, Switzerland)
|October 29, 2025
概括
图尼卡米辛抑制了DPAGT1,对N-糖甘生物合成至关重要,抑制了癌症的生长. 新的DPAGT1抑制剂对向癌症治疗有前途,克服了尼卡米辛的毒性.
科学领域:
- 生物化学 生物化学
- 癌症生物学 癌症生物学
- 药物发现 药物发现 药物发现
背景情况:
- 图尼卡米辛通过抑制DPAGT1,这是启动N-甘氨酸生物合成的酶,从而诱导内 плазма网膜 (ER) 应激.
- 异常的N-甘氨酸结构是许多固体瘤的特征,影响瘤过程.
- 图尼卡米辛抑制瘤扩散,转移和血管生成,但具有高毒性和缺乏选择性.
研究的目的:
- 突出DPAGT1作为一种新的抗癌点.
- 审查选择性DPAGT1抑制剂的发展.
- 探索在瘤学中用糖化向治疗的潜力.
主要方法:
- 在癌症中对突尼卡米辛,DPAGT1和N-甘氨酸生物合成的现有文献的审查.
- 对DPAGT1抑制剂设计和临床前疗效的研究分析.
- 讨论开发向癌症治疗的挑战和进展.
主要成果:
- DPAGT1被确定为抗癌药物开发的可处理性目标.
- 选择性DPAGT1抑制剂显示出克服尼卡米辛的局限性的潜力.
- 抑制剂设计的进步为针对糖化的有效瘤治疗提供了途径.
结论:
- 准DPAGT1为癌症治疗提供了一个有前途的策略.
- 选择性DPAGT1抑制剂的开发可能会导致新的,不太有毒的癌症治疗方法.
- 以糖基化为向的疗法代表了瘤学的新发展前沿.
更多相关视频
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
29.7K
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
4.3K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
